Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Sulzer Ltd
  6. News
  7. Summary
    SUN   CH0038388911

SULZER LTD

(SUN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sulzer : Midyear results 2021 presentation (pdf)

07/22/2021 | 12:28am EDT

H1 2021 results

Greg Poux-Guillaume, CEO | Jill Lee, CFO | July 22, 2021

Disclaimer

IMPORTANT

The presentation has been prepared by Sulzer Ltd. ("Sulzer", and together with its subsidiaries, the "Sulzer Group") and the Applicator System ("APS") division of the Sulzer Group to be spun off and re-named medmix ("medmix") for information and background purposes only. This document is not, and should not be construed as, a prospectus or offering document, and has not been reviewed or approved by any regulatory or supervisory authority. The information does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or a solicitation or invitation of any offer to subscribe for or purchase any loans or securities of or make an investment in Sulzer or any other member of the Sulzer Group or medmix or any of its subsidiaries or any other entity in any jurisdiction, and nothing contained therein shall form the basis of, or be relied on in connection with, any contract or commitment whatsoever, in particular, it must not be used in making any investment decision. Any decision to invest in securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

This presentation includes financial information which has been derived from the historical combined and carve-out financial statements of medmix for the years 2018, 2019 and 2020 (the "Relevant Period") (the "Combined and Carve-out Financial Statements"), which are currently in draft form and unaudited and therefore continue to be subject to change prior to completion of the audit and release of the related audit report. While the Combined and Carve-out Financial Statements have been prepared on a carve-out basis from the consolidated financial statements of Sulzer, their preparation required that certain changes be made to the financial information as presented for the APS division in Sulzer's consolidated financial statements for the Relevant Period. Accordingly, the financial information derived from the draft Combined and Carve-Out Financial Statements of medmix for the Relevant Period and from the consolidated financial statements of Sulzer for its APS division for the Relevant Period may not be fully comparable. This presentation also includes certain quarterly information of medmix for the year 2020 and the first quarter of 2021, which has been not been subject to an audit or audit review and may be subject to change. Certain financial data included in this presentation consists of non-IFRS financial measures. These non-IFRS financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with IFRS.

No representation, warranty or undertaking, express or implied, is made by Sulzer, medmix or any of their respective affiliates or directors, officers, employees, agents or advisers ("Representatives") or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein or any other statement made or purported to be made in connection with Sulzer, the Sulzer Group or medmix and any of its subsidiaries, for any purpose whatsoever, including but not limited to any investment considerations. No responsibility, obligation or liability whatsoever, whether arising in tort, contract or otherwise, is or will be accepted by Sulzer, medmix or any of their respective Representatives or any other person for any loss, cost or damage howsoever arising from any use of the Information, or for information or opinions or for any errors, omissions or misstatements contained therein or otherwise arising in connection therewith.

This presentation includes market share and industry data obtained by Sulzer from official or third-party sources. Sulzer may not have access to the facts and assumptions underlying the numerical data, market data and other information extracted from public sources. Third-party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. Neither Sulzer, medmix nor any of their respective Representatives or any other person are able to verify such information, and assume no responsibility for the correctness of any such information. In addition, certain of the industry and market data included in this presentation, if not labelled otherwise, are derived from Sulzer's internal research and estimates based on the knowledge and experience of its management in the markets in which it operates. Accordingly, no undue reliance should be placed on any of the numerical or market data contained in this presentation.

This presentation contains forward-looking statements, including but not limited to, projections of financial developments, market activities, future performance of products and solutions or planned transactions, which involve risks and uncertainties and are based on certain assumptions. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results, performance or events to differ materially from the statements made herein. If any of these risks and uncertainties materializes or if the assumptions underlying any of Sulzer's or medmix' forward-looking statements prove to be incorrect, the actual results may be materially different from those Sulzer or medmix express or imply by such statements. Neither Sulzer nor medmix intend or assume any obligation to update these forward-looking statements since they are based solely on the circumstances at the date of their publication.

This presentation constitutes neither an offer to sell nor a solicitation to buy securities. This presentation shall also not be considered as a prospectus or similar notice in accordance with article 35 et seqq. FinSA and/or article 69 FinSA . Any offer and listing of securities shall be made exclusively by and based on a securities prospectus to be published. Any investment decision regarding publicly offered securities shall only be made based on the securities prospectus.

Any offering of securities mentioned herein will not be registered under the United States Securities Act of 1933, as amended (the "Act"), and such securities may not be offered or sold in the United States of America absent registration or an applicable exemption from registration requirements under the Act.

This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 (as amended, the "Prospectus Regulation"). Any offer of securities in any Member State of the European Economic Area will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of securities.

This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 as it forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018 (the "UK Prospectus Regulation"). Any offer of securities in the United Kingdom will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of securities.

In addition, in the United Kingdom, this presentation is being made, and is directed only at (i) persons falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act (Financial

Promotion) Order 2005 (as amended, the "Order"), (ii) high net worth entities falling within Articles 49(2)(a) to (d) of the Order, (iii) persons falling within Article 43(2) of the Order, including existing members and creditors of Sulzer, or (iv)

persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) may otherwise lawfully be communicated or caused to be communicated (all such persons described in (i) to (iv) above together being referred to as "Relevant Persons"). In the UK, any investment or investment activity to which this presentation or any related documents and/or materials relate is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person in the UK who is not a Relevant Person should not act or rely on this presentation or any related documents and/or materials or any of its or their contents.

Note on Alternative Performance Measures (APM): all bridges from APM to reported figures can be found in the financial section of Sulzer's half-year report 2021.

H1 2021 results

July 22, 2021

2

Business Review

H1 2021 results

3

H1 2021 highlights

  • Orders up 12% (+7% organic) in Q2 YOY, +8% sequentially
  • Sales up 9% (6% organic) in H1 YOY
  • Operational Profitability reached 10.0% in H1, up 250 bps YOY
  • FCF tripled YOY to reach H1 record CHF117m
  • Addition of Nordic Water gives Sulzer one of the broadest range of water pumping and treatment solutions
  • Applicator Systems division spin off to shareholders announced, to be renamed medmix and listed separately on SIX
  • Split will enable Sulzer and medmix to leverage the full potential of each business to maximize profitable growth

July 22, 2021

4

H1 2021 Orders and Profit split

Positive trends in all divisions

APS

15%

APS

PE

Asia

25%

19%

24%

EMEA

PE

34%

44%

CT

Orders

Op. Profit

Orders

1'820

172

1'820

20%

mCHF

mCHF

mCHF

CT

16%

RESAmericas

40%32%

RES

31%

Highlights

  • Service (RES): order continue to show positive momentum, sales and profitability above last year
  • Pumps (PE): strong order growth in Water (> 40% of PE), Industry robust, Energy at trough
  • Chemtech (CT): growth on all metrics. Renewables business continues to show momentum
  • Applicators (APS): high performing Dental and Industry segments, first customer for new D-Flex platform in Drug Delivery

H1 2021 results

July 22, 2021

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Sulzer AG published this content on 22 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 July 2021 04:27:10 UTC.


ę Publicnow 2021
All news about SULZER LTD
08:12aSULZER : XJ 900 was awarded Product of the Year at the Pump Industry Awards
PU
09/22Medmix Commences $325 Million Capital Raise
MT
09/22SULZER : Medmix AG launches share offering and sets price range at CHF 37 to CHF 47 per sh..
PU
09/20Sulzer Shareholders Clear Spin-Off of Applicator Systems Unit
CI
09/20SULZER : Shareholders OK Demerger, Incorporation of Medmix
MT
09/20SULZER : shareholders approve demerger plan and incorporation of medmix AG and all other p..
PU
09/07GLOBAL MARKETS LIVE : Ryanair, Hyundai, Adecco, Goldman Sachs, JD.com...
09/07SULZER : Morgan Stanley Lifts Price Target on Sulzer, Maintains Equalweight/Cautious Recom..
MT
09/06SULZER : to Spin Off, Float Applicator Systems Division
MT
08/31SULZER : Mixpac receives EcoVadis award
PU
More news
Analyst Recommendations on SULZER LTD
More recommendations
Financials
Sales 2021 3 458 M 3 737 M 3 737 M
Net income 2021 161 M 174 M 174 M
Net Debt 2021 319 M 345 M 345 M
P/E ratio 2021 29,2x
Yield 2021 2,97%
Capitalization 4 588 M 4 958 M 4 959 M
EV / Sales 2021 1,42x
EV / Sales 2022 1,30x
Nbr of Employees 15 054
Free-Float 49,4%
Chart SULZER LTD
Duration : Period :
Sulzer Ltd Technical Analysis Chart | SUN | CH0038388911 | MarketScreener
Technical analysis trends SULZER LTD
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 136,80 CHF
Average target price 134,20 CHF
Spread / Average Target -1,90%
EPS Revisions
Managers and Directors
GrÚgoire Poux-Guillaume Chief Executive Officer
Jill Lee Chief Financial Officer
Peter D. L÷scher Chairman
Gerhard Roiss Independent Non-Executive Director
Hanne Birgitte Sorensen Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SULZER LTD46.94%5 010
ATLAS COPCO AB36.88%77 333
FANUC CORPORATION0.26%43 291
PARKER-HANNIFIN CORPORATION4.77%37 581
TECHTRONIC INDUSTRIES COMPANY LIMITED43.76%37 506
SANDVIK AB4.57%30 578